DiscoverPop Health PodcastBeyond the Hype: What GLP-1s Mean for Policy and Employers
Beyond the Hype: What GLP-1s Mean for Policy and Employers

Beyond the Hype: What GLP-1s Mean for Policy and Employers

Update: 2025-09-23
Share

Description

GLP-1 medications like Ozempic and Wegovy have quickly moved from niche treatments to the center of high-stakes conversations across payers about cost, access, and coverage. In this episode, Coral Partner Alison Falb talks with Laura Rudder Huff, Vice President at Gallagher Research & Insights, about how the rise of GLP-1s is shaping employer benefit strategies, equity considerations, and policy debates.  

Comments 
00:00
00:00
x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

Beyond the Hype: What GLP-1s Mean for Policy and Employers

Beyond the Hype: What GLP-1s Mean for Policy and Employers

Meg and Melissa